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There is increasing evidence that the presence of a systemic inflammatory response plays an important role in predicting survival in
patients with colorectal cancer. However, it is not clear what components of the systemic inflammatory response best predict
survival. The aim of the present study was to compare the prognostic value of an inflammation-based prognostic score (modified
Glasgow Prognostic Score (Mgps) 0¼C-reactive protein o10mgl
 1,1 ¼C-reactive protein 410mgl
 1, and 2¼C-reactive
protein 410mgl
 1 and albumino35gl
 1) with that of components of the white cell count (neutrophils, lymphocytes, monocytes
and platelets using standard thresholds) in patients with colorectal cancer. Two patient groups were studied: 149 patients who
underwent potentially curative resection for colorectal cancer and 84 patients who had synchronous unresectable liver metastases. In
those patients who underwent potentially curative resection the minimum follow-up was 36 months and 20 patients died of their
cancer. On multivariate survival analysis only TNM stage (HR 3.75, 95% CI 1.54–9.17, P¼0.004), monocyte count (HR 3.79, 95% CI
1.29–11.12, P¼0.015) and mGPS (HR 2.21, 95% CI 1.11–4.41, P¼0.024) were independently associated with cancer-specific
survival. In patients with synchronous unresectable liver metastases the minimum follow-up was 6 months and 71 patients died of
their cancer. On multivariate survival analysis only single liver metastasis 45cm (HR 1.78, 95% CI 0.99–3.21, P¼0.054), extra-
hepatic disease (HR 2.09, 95% CI 1.05–4.17, P¼0.036), chemotherapy treatment (HR 2.40, 95% CI 1.82–3.17, Po0.001) and
mGPS (HR 1.44, 95% CI 1.01–2.04, P¼0.043) were independently associated with cancer-specific survival. In summary, markers of
the systemic inflammatory response are associated with poor outcome in patients with either primary operable or synchronous
unresectable colorectal cancer. An acute-phase protein-based prognostic score, the mGPS, appears to be a superior predictor of
survival compared with the cellular components of the systemic inflammatory response.
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Colorectal cancer remains the second commonest cause of cancer
death in Western Europe and North America. Each year in the
United Kingdom, there are approximately 35000 new cases and
16000 deaths attributable to the disease (Cancerstats, 2004,
www.cancerresearchuk.org). Approximately one-fifth of patients
will have colorectal liver metastases. Overall survival is poor; even
in those patients who undergo potentially curative resection, more
than one-third die within 5 years (McArdle and Hole, 2002).
It is increasingly recognised that variations in outcome in cancer
patients are not solely determined by the characteristics of the
tumour but also by the host-response factors (MacDonald, 2007).
It is now accepted that the host systemic inflammatory response
can be assessed by examining the changes in the circulating
concentrations of acute-phase proteins, such as elevated concen-
tration of C-reactive protein and low concentrations of albumin
(Gabay and Kushner, 1999; McMillan et al, 2001). It is of interest
that either singly or combined these factors have been shown to be
stage- and performance status-independent prognostic factors in
patients with a variety of inoperable cancers (Forrest et al, 2003,
2004; Al Murri et al, 2006; Crumley et al, 2006; Glen et al, 2006;
Ramsey et al, 2007). Similarly, singly these factors have been
shown to be tumour stage-independent prognostic factors, prior to
surgery, in patients with a variety of primary operable cancers
including colorectal cancer (Heys et al, 1998; Longo et al, 1998;
Nozoe et al, 1998; Longo et al, 2000; Nielsen et al, 2000; McMillan
et al, 2003). Furthermore, Wong et al (2007) showed that an
elevated C-reactive protein concentration was an independent
predictor of survival in patients undergoing potentially curative
surgery for colorectal liver metastases. Recently, the combination
of C-reactive protein and albumin, known as the Glasgow
Prognostic Score (GPS) has been evaluated pre-operatively in
patients undergoing potentially curative surgery for colorectal
cancer (McMillan et al, 2007).
However, acute-phase proteins are just one aspect of the
systemic inflammatory response (Gabay and Kushner, 1999).
There are cellular components of the systemic inflammatory
response such as neutrophils, lymphocytes, monocytes and
platelets that have been reported to have prognostic value in
patients with a variety of common solid tumours (Riesco, 1970;
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sBruckner et al, 1982; Vigano et al, 2000; Maltoni et al, 2005; Hauser
et al, 2006). Therefore, it may be that the components of the whole-
blood differential white cell count either singly or in combination
may have prognostic value in patients with either primary operable
or metastatic colorectal cancer. Indeed, Walsh et al (2005) reported
that the neutrophil/lymphocyte ratio had prognostic value in
patients undergoing surgery for colorectal cancer. However, it is
known whether such white cell measures offer prognostic value
that is independent of tumour stage or superior to the combination
of C-reactive protein and albumin (GPS).
Therefore, the aim of the present study was to examine the
relationship between selected markers of the systemic inflamma-
tory response, treatment and survival in patients with primary
operable or synchronous unresectable colorectal cancer.
PATIENTS AND METHODS
Patients
Patients with histologically proven colorectal cancer who, on the
basis of laparotomy findings and/or preoperative abdominal-
computed tomography, were considered to have undergone a
potentially curative resection or had synchronous unresectable
liver metastases and had routine laboratory measurement of white
cell, neutrophil, lymphocyte, monocyte and platelet counts,
albumin and C-reactive protein, between February 1998 and May
2006 at Glasgow Royal Infirmary were included in the study. The
tumours were staged according to the TNM criteria (AJCC, 2002).
Patients who had clinical evidence of infection or other
inflammatory condition were excluded from the study.
The extent of deprivation was defined using the Carstairs
deprivation index (Carstairs and Morris, 1991). This is an area-
based measure derived from the 1991 census, using the postcode of
residence at diagnosis, which divides the score into a seven-point
index. For illustrative purposes, the results are presented by
amalgamating the seven categories into three groups: affluent
(categories 1 and 2), intermediate (categories 3–5) and deprived
(categories 6 and 7). The Carstairs deprivation index has been
extensively utilised in cancer patients and is particularly appro-
priate for use in the central belt of Scotland (Hole and McArdle,
2002).
Patients with synchronous colorectal liver metastases either had
their primary colorectal cancer excised, stented, or by-passed due
to obstructive symptoms or chemo/radiotherapy.
The study was approved by the Research Ethics Committee,
Royal Infirmary, Glasgow.
Methods
The coefficient of variation for the routine laboratory measure-
ments of absolute white cell, neutrophil, lymphocyte, monocyte
and platelet counts, albumin and C-reactive protein, over the range
of measurement, was less than 10% as established by routine
quality control procedures. The limit of detection of the assay was
a C-reactive protein concentration lower than 6mgl
 1.
The GPS was constructed as previously described (Forrest et al,
2003). Briefly, patients with both an elevated C-reactive protein
(410mgl
 1) and hypoalbuminaemia (o35gl
 1) were allocated a
score of 2. Patients in whom only one of these biochemical
abnormalities was present were allocated a score of 1. Patients in
whom neither of these abnormalities was present were allocated a
score of 0.
Recently, however, this has been modified based on evidence
that hypoalbuminaemia, in patients without an elevated C-reactive
protein concentration, had no significant association with cancer-
specific survival. Therefore, patients with an elevated C-reactive
protein were assigned a modified GPS score (mGPS) of 1 or 2
depending on the absence or presence of hypoalbuminaemia
(McMillan et al, 2007).
Statistics
Grouping of the variables white cell, neutrophil, lymphocyte,
monocyte and platelet counts was carried out using standard
thresholds (Riesco, 1970; Bruckner et al, 1982; Vigano et al, 2000;
Maltoni et al, 2005; Hauser et al, 2006). Survival analysis of the
group variables was performed using the Cox proportional hazard
model. Deaths up to the end of April 2007 were included in the
analysis. Multivariate survival analysis, including all significant
covariates (Po0.05 to account for multiple comparisons) was
performed using a stepwise backward procedure to derive a final
model of the variables that had a significant independent
relationship with survival. To remove a variable from the model,
the corresponding P-value had to be greater than 0.05. The
relationships between the mGPS and other variables were analysed
using the Mantel–Haenszel (X
2) test for trend as appropriate.
Analysis was performed using SPSS software (SPSS Inc., Chicago,
IL, USA).
RESULTS
Two patient groups were studied: 149 patients who underwent
potentially curative resection for colorectal cancer and 84 patients
who had synchronous unresectable liver metastases (Table 1).
Overall, the majority of patients were aged 65 years or more, were
male, were deprived, had colonic tumours and had TNM stage I/II
tumours. The majority of patients had white cell, neutrophil,
lymphocyte, monocyte and platelet counts and albumin concen-
trations in the normal range. In contrast, C-reactive protein and
thus the mGPS were elevated in the majority of patients.
Patients with synchronous unresectable liver metastases had
higher white cell, neutrophil, lymphocyte and monocyte counts (all
Po0.01) and C-reactive and mGPS (both Po0.001) compared with
primary operable disease (Table 1). On follow-up more patients
with synchronous unresectable liver metastases died of their
cancer (Po0.001).
The relationship between clinicopathological characteristics,
systemic inflammatory response and survival in patients with
primary operable cancer is shown in Table 2. The minimum
follow-up was 36 months, maximum 73 months; the median
follow-up of the survivors was 48 months. During the follow-up
period 45 patients died, 20 patients of their cancer and 25 of
intercurrent disease. On univariate survival analysis, age (Po0.01),
TNM stage (Po0.05), white cell (Pp0.001), neutrophil (Po0.01),
monocyte (Po0.01), and platelet (Po0.05) counts and mGPS
(Pp0.001) were significantly associated with overall survival
(Table 2). On multivariate survival analysis of these significant
variables only age (HR 1.74, 95% CI 1.19–2.56, P¼0.005), TNM
stage (HR 2.28, 95% CI 1.36–3.82, P¼0.002), monocyte count (HR
3.11, 95% CI 1.42–6.82, P¼0.005) and mGPS (HR 2.08, 95% CI
1.32–3.28, P¼0.002) were independently associated with overall
survival.
On univariate survival analysis, TNM stage (Po0.05), white cell
(Po0.01), neutrophil (Po0.01), monocyte (Pp0.01), and platelet
(Po0.05) counts and mGPS (Po0.05) were significantly associated
with poorer cancer-specific survival (Table 2). On multivariate
survival analysis of these significant variables, only TNM stage
(HR 3.75, 95% CI 1.54–9.17, P¼0.004), monocyte count (HR 3.79,
95% CI 1.29–11.12, P¼0.015) and mGPS (HR 2.21, 95% CI 1.11–
4.41, P¼0.024) were independently associated with cancer-specific
survival. When mGPS was excluded from the model, on multi-
variate analysis only TNM stage (HR 2.49, 95% CI 1.11–5.61,
P¼0.0274) and white cell count (HR 2.22, 95% CI 1.28–3.84,
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sP¼0.004) were independently associated with cancer-specific
survival.
The relationship between clinicopathological characteristics,
systemic inflammatory response and survival in patients with
unresectable colorectal liver metastases is shown in Table 3. The
minimum follow-up was 6 months, maximum 73 months; the
median follow-up of the survivors was 12 months. A total of 71
(85%) patients died of their disease during the follow-up period.
On univariate analysis, age (Po0.05), any single liver metastasis
45cm (Po0.01), extra-hepatic disease (Po0.05), chemotherapy
(Po0.0001) and mGPS (Pp0.001) were significantly associated
with poorer cancer-specific survival (Table 3). On multivariate
analysis of these significant variables, including treatment, only
single liver metastasis 45cm (HR 1.78, 95% CI 0.99–3.21,
P¼0.054), extra-hepatic disease (HR 2.09, 95% CI 1.05–4.17,
P¼0.036), chemotherapy treatment (HR 2.40, 95% CI 1.82–3.17,
Po0.001) and mGPS (HR 1.44, 95% CI 1.01–2.04, P¼0.043) were
independently associated with poorer cancer-specific survival.
When mGPS was excluded from the model, on multivariate
analysis only single liver metastasis 45cm (HR 1.97, 95% CI 1.12–
3.47, P¼0.018), extra-hepatic disease (HR 2.02, 95% CI 1.02–4.01,
P¼0.043) and chemotherapy treatment (HR 2.29, 95% CI 1.76–
2.98, Po0.001) were independently associated with cancer-specific
survival.
The relationship between the mGPS and clinicopathological
characteristics in all colorectal cancer patients is shown in Table 4.
An increase in the mGPS was associated with an increase in TNM
stage (Po0.001), higher white cell (Po0.001), neutrophil
(Po0.001), monocyte (Po0.01) and platelet (Po0.001) counts
and also the neutrophil lymphocyte ratio (Po0.001). An increase
in the mGPS was associated with a lower lymphocyte count
(Po0.01).
The relationship between TNM stage, the mGPS and cancer-
specific survival is shown in Figures 1 and 2 respectively.
Table 2 The relationship between clinicopathological characteristics, the systemic inflammatory response and survival in patients with primary operable
colorectal cancer; univariate analysis
Overall survival Cancer-specific survival
Patients (n¼149) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (o65/65–74/X75 years) 48/52/49 1.65 (1.13–2.39) 0.009 1.48 (0.85–2.57) 0.166
Sex (male/female) 81/68 0.76 (0.42–1.38) 0.371 1.15 (0.48–2.75) 0.762
Deprivation (1-2/3–5/6–7)
a 5/66/78 0.98 (0.82–1.16) 0.799 0.87 (0.68–1.13) 0.298
Tumour site (colon/rectum) 83/66 0.96 (0.54–1.74) 0.903 0.80 (0.33–1.95) 0.621
TNM Stage (I/II/III) 22/62/65 1.79 (1.13–2.85) 0.014 2.63 (1.19–5.80) 0.016
Neo-adjuvant therapy (yes/no) 11/138 0.55 (0.13–2.25) 0.402 1.30 (0.30–5.62) 0.722
Adjuvant therapy (yes/no) 52/97 0.89 (0.48–1.66) 0.718 1.79 (0.74–4.29) 0.195
White cell count (o8.5/8.5–11/411 10
9l
 1) 92/40/17 1.92 (1.32–2.81) 0.001 2.40 (1.38–4.16) 0.002
Neutrophil count (o7.5/X7.5 10
9l
 1) 129/20 2.90 (1.46–5.73) 0.002 3.77 (1.44–9.82) 0.007
Lymphocyte count (43.0/1.0–3.0/o1.0 10
9l
 1) 7/131/11 0.72 (0.29–1.80) 0.484 0.30 (0.09–1.01) 0.053
Monocyte count (p0.9/40.9 10
9l
 1) 132/17 2.86 (1.38–5.95) 0.005 3.78 (1.37–10.40) 0.010
Platelet count (o400/X400 10
3l
 1) 117/32 2.10 (1.12–3.95) 0.022 2.53 (1.01–6.35) 0.048
Neutrophil/lymphocyte ratio (o5/X5) 124/25 1.68 (0.83–3.39) 0.150 1.49 (0.50–4.45) 0.479
mGPS (0/1/2) 88/48/13 2.07 (1.35–3.16) 0.001 2.01 (1.06–3.80) 0.032
TNM¼tumour, node, metastases; mGPS¼modified Glasgow Prognostic Score; CI¼confidence interval.
aIndividual deprivation categories were used in the statistical analysis.
Table 1 The relationship between clinicopathological characteristics, the systemic inflammatory response and survival in patients with colorectal cancer
Primary operable (n¼149) Synchronous unresectable (n¼84) P-value
Age (o65/65–74/475 years) 48/52/49 34/27/23 0.215
Sex (male/female) 81/68 48/36 0.683
Deprivation (1–2/3–5/6–7)
a 5/66/78 7/33/44 0.981
Tumour site (colon/rectum) 83/66 52/32 0.358
TNM Stage (I/II/III/IV) 22/62/65/0 0/0/0/84 o0.001
White cell count (o8.5/8.5–11/411 10
9l
 1) 82/40/17 30/27/27 o0.001
Neutrophil count (o7.5/47.5 10
9l
 1) 129/20 49/35 o0.001
Lymphocyte count (43.0/1.0–3.0/o1.0 10
9l
 1) 7/131/11 2/66/16 0.008
Neutrophil/lymphocyte ratio (o5/45) 124/25 48/36 o0.001
Monocyte count (o0.9/40.9 10
9l
 1) 132/17 61/23 0.002
Platelet count (o400/4400 10
3l
 1) 117/32 55/27 0.057
C-reactive protein (o10/410mgl
 1) 88/61 17/64 o0.001
Albumin (435/o35gl
 1) 135/14 55/29 o0.001




Non-cancer 25 0 o0.001
TNM¼tumour, node, metastases; mGPS¼modified Glasgow Prognostic Score.
aIndividual deprivation categories were used in the statistical analysis.
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In the present study a number of cellular components of the
systemic inflammatory response were associated with cancer-
specific survival in patients with colorectal cancer and therefore
confirm previous work in other tumour types. However, compared
with a score (mGPS) based on the acute-phase proteins, C-reactive
protein and albumin, these cellular components of the white cell
count, did not consistently have independent prognostic value.
Table 3 The relationship between clinicopathological characteristics, the systemic inflammatory response and cancer-specific survival in patients with





Age (o65/65–74/X75 years) 34/27/23 1.47 (1.08–2.00) 0.0139
Sex (male/female) 48/36 1.13 (0.70–1.82) 0.6176
Deprivation (1–2/3–5/6–7)
a 7/33/44 0.98 (0.85–1.12) 0.7336
Tumour site (colon/rectum) 52/32 1.14 (0.70–1.85) 0.6048
Emergency presentation (no/yes) 75/9 1.56 (0.74–3.27) 0.2423
No. of liver metastases (1/41) 4/80 2.05 (0.64–6.57) 0.2270
Any single liver metastasis (p5/45cm) 36/38 2.19 (1.30–3.67) 0.0030
Extra-hepatic disease (no/yes) 64/20 2.06 (1.16–3.67) 0.0140
Therapy: chemotherapy+primary resected or stent/chemotherapy alone/primary resected
or stent alone/no active treatment
28/20/23/13 2.16 (1.71–2.73) o0.0001
White cell count (o8.5/8.5–11/411 10
9l
 1) 30/27/27 1.31 (0.99–1.75) 0.0631
Neutrophil count (o7.5/X7.5 10
9l
 1) 49/35 1.57 (0.98–2.53) 0.0627
Lymphocyte count (43.0/1.0–3.0/o1.0 10
9l
 1) 2/66/16 1.65 (0.93–2.93) 0.0864
Monocyte count (p0.9/40.9 10
9l
 1) 61/23 1.32 (0.77–2.25) 0.3122
Platelet count (o400/X400 10
3l
 1) 55/27 1.36 (0.82–2.25) 0.2338
Neutrophil/lymphocyte ratio (o5/X5) 48/36 1.35 (0.84–2.16) 0.2200
mGPS (0/1/2) 17/44/23 1.46 (1.05–2.03) 0.0243
mGPS¼modified Glasgow Prognostic Score; CI¼confidence interval.
aIndividual deprivation categories were used in the statistical analysis.
Table 4 The relationship between the mGPS and clinicopathological characteristics in patients with colorectal cancer (n¼233)
mGPS 0 (n¼105) mGPS 1 (n¼92) mGPS 2 (n¼36) P-value
Age (o65/65–74/475 years) 37/38/30 34/30/28 11/11/14 0.431
Sex (male/female) 62/43 47/45 20/16 0.487
Deprivation (1–2/3–5/6–7)
a 6/45/54 4/41/47 2/13/21 0.584
Tumour site (colon/rectum) 54/51 59/33 22/14 0.142
TNM Stage (I/II/III/IV) 15/30/43/17 6/25/17/44 1/7/5/23 o0.001
White cell count (o8.5/8.5–11/411 10
9l
 1) 75/23/7 37/33/22 10/11/15 o0.001
Neutrophil count (o7.5/47.5 10
9l
 1) 96/9 65/27 17/19 o0.001
Lymphocyte count (43.0/1.0–3.0/o1.0 10
9l
 1) 3/97/5 6/74/12 0/26/10 0.002
Monocyte count (o0.9/40.9 10
9l
 1) 95/10 74/18 24/12 0.001
Platelet count (o400/4400 10
3l
 1) 93/11 62/30 17/18 o0.001
Neutrophil/lymphocyte ratio (o5/45) 96/9 61/31 15/21 o0.001
TNM¼tumour, node, metastases; mGPS¼modified Glasgow Prognostic Score.
aIndividual deprivation categories were used in the statistical analysis.
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Figure 1 The relationship between TNM stage (I, II, III and IV from top
to bottom) and cancer-specific survival in patients with colorectal cancer.
Survival (months)































Figure 2 The relationship between mGPS (0, 1 and 2 from top to
bottom) and cancer-specific survival in patients with colorectal cancer.
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sTherefore, it would appear that the mGPS is superior to these
cellular components, in particular the neutrophil/lymphocyte
ratio, in predicting survival at different tumour stages in patients
with colorectal cancer.
The results of the present study may also offer insight into the
nature of the relationship between the systemic inflammatory
response and survival in patients with primary operable and
metastatic unresectable colorectal cancer. A plausible explanation
is that an elevated mGPS may reflect compromised acquired
immunity as it was associated with an increase in lymphopenia.
An alternative explanation is that an elevated mGPS may reflect
altered innate immunity as it was also associated with increased
numbers neutrophils and monocytes. However, given that higher
neutrophil and monocyte counts were more strongly associated
with poorer cancer-specific survival this may suggest that of
activation of the innate, rather than downregulation of the
acquired immune system, is the most important factor in
determining poor outcome in patients with colorectal cancer. It
may be that downregulation of these innate cell types should
targeted in the treatment of patients with colorectal cancer.
With respect to metastatic unresectable disease there is now
considerable evidence that chronic activation of the systemic
inflammatory response is associated with an increase in weight
loss, in particular the loss of lean tissue, with the consequent
increase in fatigue, decreased performance status and survival
(Kotler and Cachexia, 2000; MacDonald, 2007).
Irrespective of the mechanisms involved, we believe that the
presence or absence of a systemic inflammatory response as
measured by the mGPS should be evaluated, prior to treatment, in
patients with colorectal cancer and should be used in the risk
stratification of such patients. In summary, markers of the
systemic inflammatory response are associated with poor outcome
in patients with either primary operable or synchronous un-
resectable colorectal cancer. An acute-phase protein-based prog-
nostic score, the mGPS, appears to be a superior predictor of
survival compared with cellular components of the systemic
inflammatory response.
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